Efficacy of Sublingual Fentanyl vs. Oral Morphine for Cancer-Related Breakthrough Pain
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Breakthrough cancer pain (BTcP) is recognized as a clinically significant complication of chronic cancer pain with most BTcP episodes peaking in intensity within a few minutes and lasting for approximately 30 min. Although a number of rapid-onset fentanyl preparations have been developed in the last decade, BTcP is still typically managed through the use of rescue doses of oral morphine but a comparative study of sublingual fentanyl and oral morphine is still lacking. The aim of this study was to determine the efficacy, tolerability, and patient satisfaction of sublingual fentanyl citrate (SLF) and oral morphine solution (OM) in the treatment of BTcP.
In this prospective, longitudinal, controlled-study, 40 patients with BTcP were allocated to receive oral morphine (OM) or sublingual fentanyl (SLF). Pain intensity level on a 0–10 numerical rating visual analog scale (VAS), frequency of BTcP throughout the day, onset of relief (0–5, 6–10, 11–15, or over 16 min), time required for dose titration, patient satisfaction and adverse effects were assessed at 3, 7, 15, and 30 days after starting the treatment.
Mean doses of opioids for BTcP were 235 ± 23.4 μg (SLF) and 38 ± 5.2 mg (OM). The mean pain intensity levels were significantly lower with SLF than OM at 3 days (6.0 vs. 6.95; p = 0,001), 7 days (4.15 vs. 6.25, p < 0.001), 15 days (3.45 vs. 5.35, p < 0.001), and 30 days (3.05 vs. 4.45, p < 0.001). SLF provided significantly faster relief for BTcP than OM (p < 0.001) with a shorter dose titration period (mean 6.6 ± 3.3 vs. 13.3 ± 4.9 days; p < 0.001) and better satisfaction scores and with a very good safety profile.
Administration of SLF might provide a more effective treatment option than oral morphine for BTcP.
- American Pain Society (APS). Principles of analgesic use in the treatment of acute pain and cancer pain. 6th ed. Glenview: American Pain Society; 2008.
- National Comprehensive Cancer Network. Clinical practice guidelines in oncology for adult cancer pain. V.1.2010. Fort Washington: National Comprehensive Cancer Network; 2010. http://www.jnccn.org/content/8/9/1046.full.pdf+html. Accessed September 6, 2013.
- Portenoy RK, Payne D, Jacobson P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129–34. CrossRef
- Portenoy RK, Forbes K, Lussier D, Hanks G. Difficult pain problems: an integrated approach. In: Doyle D, Hanks G, Cherny N, Calman K, editors. Oxford textbook of palliative medicine. 3rd ed. Oxford: Oxford University Press; 2004. p. 438–58.
- Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev. 1998;24:425–32. CrossRef
- Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain. Cancer. 2002;94:832–9. CrossRef
- Haugen DF, Hjermstad MJ, Hagen N, Caraceni A, Kaasa S. European Palliative Care Research Collaborative (EPCRC) assessment and classification of cancer breakthrough pain: a systematic literature review. Pain. 2010;149:476–82. CrossRef
- Gómez-Batiste X, Madrid F, Moreno F, et al. Breakthrough cancer pain: prevalence and characteristics in patients in Catalonia, Spain. J Pain Symptom Manage. 2002;24:44–52.
- Caraceni A, Martini C, Zecca E, et al. Working group of an IASP task force on cancer pain breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med. 2004;18:177–83. CrossRef
- Foley KM. Pain assessment and cancer pain syndromes. In: Oxford textbook of palliative medicine. 2nd ed. New York: Oxford Medical Publications; 1998. p. 310–30.
- Portenoy R, Hagen N. Breakthrough pain: definition, prevalence and characteristics. Pain. 1990;41:273–81. CrossRef
- Fine PG, Marcus M, Just De Voer A, Van der Oord B. An open label study of oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain. Pain. 1991;45:149–53. CrossRef
- Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulphate immediate release (MSIR). Pain. 2001;91(1–2):123–30. CrossRef
- Greco MT, Corli O, Montanari M, Deandrea S, Zagonel V, Apolone G. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients. Results from the Cancer Pain Outcome Research Study Group. Clin J Pain. 2011;27(1):9–18. CrossRef
- Mercadante S, Costanzo BV, Fusco F, Buttà V, Vitrano V, Casuccio A. Breakthrough pain in advanced cancer patients followed at home: a longitudinal study. J Pain Symptom Manage. 2009;38:554–60. CrossRef
- Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20:1420–33. CrossRef
- Dickman A. Basics of managing breakthrough cancer pain. Pharm J. 2009;283:213e216.
- Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manage. 2003;25:9–18. CrossRef
- Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain. 2002;3:38e44. CrossRef
- Vissers DCJ, Lenre M, Tolley K, Jakobsson J, Sendersky V, Jansen JP. An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer. Value Health. 2011;14:274e281. CrossRef
- Zeppetella G. Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage. 2008;35:563e567. CrossRef
- Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2: management. Pharm Ther. 2005;30:354–61.
- Lennernäs B, Frank-Lissbrant I, Lennernäs H, Kälkner KM, Derrick R, Howell J. Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain; results from a randomized phase II study. Palliat Med. 2010;24:286–93. CrossRef
- Rauck RL, Tark M, Reyes E, et al. Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain. Curr Med Res Opin. 2009;25:2877–85. CrossRef
- Überall MA, Müller-Schwefe GH. Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin. 2011;27(7):1385–94. CrossRef
- Nalamachu S, Hassman D, Wallace MS, Dumble S, Derrick R, Howell J. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin. 2011;27:519–30. CrossRef
- Chwieduk CM, McKeage K. Fentanyl sublingual: in breakthrough pain in opioid-tolerant adults with cancer. Drugs. 2010;70(17):2281–8. CrossRef
- Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A, Westerberg M, Nyström C. In vitro and in vivo evaluation of a new sublingual tablet system for rapid oromucosal absorption using fentanylcitrate as the active substance. Eur J Pharm Sci. 2003;20(3):327–34. CrossRef
- Smith HS. Considerations in selecting rapid-onset opioids for the management of breakthrough pain. J Pain Res. 2013;6:189–200. CrossRef
- Mercadante S. Pharmacotherapy for breakthrough cancer pain. Drugs. 2012;72(2):181–90. CrossRef
- Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013;12:1–8.
- American Pain Foundation. Breakthrough cancer pain: mending the break in the continuum of care. J Pain Palliat Care Pharmacother. 2011;25(3):252–64. CrossRef
- Weinstein SM, Messina J, Xie F. Fentanyl buccal tablet for the treatment of breakthrough pain in opioid tolerant patients with chronic cancer pain. Cancer. 2009;115:2571–9. CrossRef
- Davies A, Dickman A, Reid C, et al. The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain. 2009;13:331–8. CrossRef
- Mercadante S. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing. Crit Rev Oncol/Hematol. 2011;80(3):460–5. CrossRef
- Mercadante S, Gatti A, Porzio G, et al. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses. Curr Med Res Opin. 2012;28(6):963–8. CrossRef
- Mercadante S. Oral transmucosal fentanyl citrate for breakthrough pain in treatment in cancer patients. Expert Opin Pharmacother. 2012;13(6):873–8. CrossRef
- Rubio C, Sánchez-Saugar E, Cerezo L, Vallejo M, Mañas A, de la Torre. Breakthrough pain and oral esophageal mucositis: effectiveness of sublingual fentanyl. Rep Pract Oncol Radiother. 2013;18(1):362–63.
- Davies A, Zeppetella G, Andersen S, et al. Multi-centre European study of breakthrough cancer pain: pain characteristics and patient perceptions of current and potential management strategies. Eur J Pain. 2011;15:756–63. CrossRef
- Kuo KL, Saokaew S, Stenehjem DD. The pharmacoeconomics of breakthrough cancer pain. J Pain Palliat Care Pharmacother. 2013;27(2):167–75. CrossRef
- Efficacy of Sublingual Fentanyl vs. Oral Morphine for Cancer-Related Breakthrough Pain
Advances in Therapy
Volume 31, Issue 1 , pp 107-117
- Cover Date
- Print ISSN
- Online ISSN
- Springer Healthcare
- Additional Links
- Breakthrough pain
- Oral morphine
- Sublingual fentanyl
- Industry Sectors
- Author Affiliations
- 1. Unidad del Dolor del Hospital de Alta Resolución de Guadix, Granada, Spain
- 2. Unidad del Dolor del Hospital Comarcal de Melilla, Melilla, Spain
- 3. Centro Gámez Morón de Melilla, Melilla, Spain